Comparing TNF Antagonist Survival in Spondylarthritis and Rheumatoid Arthritis
Author Information
Author(s): Carmona Loreto, Gómez-Reino Juan J
Primary Institution: Spanish Society of Rheumatology
Hypothesis
The survival and safety of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis.
Conclusion
Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis, partly due to a better safety profile.
Supporting Evidence
- Patients with spondylarthritis had a 33% lower probability of discontinuing TNF antagonists compared to those with rheumatoid arthritis.
- Adverse events occurred in 17% of spondylarthritis patients compared to 26% in rheumatoid arthritis patients.
- The hazard ratio for discontinuation in spondylarthritis was 0.66 compared to rheumatoid arthritis.
Takeaway
This study found that people with a type of arthritis called spondylarthritis do better on certain medications than those with rheumatoid arthritis.
Methodology
Data from the BIOBADASER registry was analyzed, comparing drug survival and adverse events between patients with spondylarthritis and rheumatoid arthritis.
Potential Biases
Potential confounding by indication and patient selection may affect the results.
Limitations
Measures of joint inflammation and damage were not collected, limiting the ability to adjust for baseline severity.
Participant Demographics
Patients with spondylarthritis were younger and more frequently male compared to those with rheumatoid arthritis.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI, 0.57–0.76
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website